Drug Profile
L 705106
Latest Information Update: 26 Jun 2001
Price :
$50
*
At a glance
- Originator Merck & Co
- Class Antidementias; Neuroprotectants
- Mechanism of Action Muscarinic M1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 26 Jun 2001 No-Development-Reported for Alzheimer's disease in USA (Unknown route)
- 12 Jun 1995 Preclinical development for Alzheimer's disease in USA (Unknown route)